Dd-cfDNA as a prognostic biomarker for rejection - Data from the ProActive Study

Listen to Dr. Jonathan Bromberg, ProActive Study's lead Investigator, discuss how Prospera™ accurately predicted ABMR and TCMR before biopsy-proven rejection, up to 4 months and 2 months in advanced

How Dr. Yasir Qazi embraced cell-free DNA surveillance, an unaffected approach due to the recent CMS update

Hear from our ProActive Study Investigator In this episode of our Inside the ProActive Study Podcast, Dr. Yasir Qazi talks to us about: • His dd-cfDNA “surveillance journey” and protocol development.

How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance, in-line with ASTS recommended use

In this episode of our Inside the ProActive Study Podcast, Dr. Matthew Cooper shares his insights on: • Utilizing cfDNA alongside DSA and biopsies before implementing his dd-cfDNA surveillance protoc

How Dr. Millie Samaniego bridged the gap between study use and routine care by extending protocolized use

In this episode of our Inside the ProActive Study Podcast, Dr. Millie Samaniego-Picota tells us about: • Her experience expanding the ProActive Study Protocol schedule to all her patients • How her

Inside the ProActive Study- How Dr Sanjeev Akkina and Dr. Jessica Coleman approach the continuity of transplant recipient care

How Dr. Anand championed a surveillance protocol informed by his deep experience and research

How Dr. Lozano Guzman brought cfDNA surveillance to his pediatric transplant recipients

How Dr. Batarse advocates for his patients upon early recognition of subtle rejection using cfDNA